(57) successfully converted an FDA-approved MEK inhibitor into a ferrous iron-activatable drug conjugate (FeADC), which showed potent MAPK blockade in tumor cells with KRAS mutations, while sparing normal tissues. This evidence concerns the gene KRAS and neoplasm.